Oral combination chemotherapy (CT) in the treatment of AIDS-associated Hodgkin's disease (HD) (Meeting abstract).

Important note: Information in this article was accurate in 1997. The state of the art may have changed since the publication date.

Oral combination chemotherapy (CT) in the treatment of AIDS-associated Hodgkin's disease (HD) (Meeting abstract).

Proc Annu Meet Am Soc Clin Oncol; 15:A858 1996. Unique Identifier : AIDSLINE ICDB/97635858
Remick S; Doshi S; Bibighaus M; Eckstein A; Ramnes C; McSharry J; Rustau P; Pearce T; Albany Medical College, Albany, NY

Abstract: We reported the results of an oral-based combination CT regimen given to patients (pts) with AIDS-related non-Hodgkin's lymphoma repeated at 6 week intervals consisting of CCNU 100 mg/m2 d 1 (odd cycles); VP-16 200 mg/m2 d 1-3; cyclophosphamide 100 mg/m2 and procarbazine 100 mg/m2 d 22-31 (JCO; 11:1961 1993). We have subsequently added G-CSF (5 u/kg SC daily, d 5-21 and d 33-42) to the regimen. Procarbazine is likely the most active single-agent for pts with HD; all of the other drugs in this regimen have known single-agent activity in HD as well; and the rationale for exploring an oral regimen in AIDS-associated HD is attractive. Six male patients with good PS (0-2), median CD4 lymphocyte count of 152 cells/mm3 (range 29-524), and biopsy proven HD have been treated. Four pts had stage IVB; 2 pts stage IIIB; and 3 pts had bone marrow involvement. A total of 20 cycles of therapy have been administered. Nine cycles (45%) have been associated with grade 3 (6 cycles) and grade 4 (3 cycles) leukopenia. Seven cycles (35%) have been associated with grade 3 (3 cycles) and grade 4 (4 cycles) thrombocytopenia. There has been one toxic death in a pt who developed sepsis following a procedural complication. There has been no other severe end organ toxicity. Four pts have achieved a partial remission (67%). Median survival is 7 mo (range 2.5-14). Two pts remain alive at 13 and 14 mo. This regimen appears active in AIDS-associated HD and is worthy of further clinical evaluation.

Keywords: Acquired Immunodeficiency Syndrome/*COMPLICATIONS Administration, Oral Antineoplastic Agents, Combined/ADMINISTRATION & DOSAGE/ADVERSE EFFECTS/*THERAPEUTIC USE Cyclophosphamide/ADMINISTRATION & DOSAGE Etoposide/ADMINISTRATION & DOSAGE Hodgkin's Disease/COMPLICATIONS/*DRUG THERAPY Human Lomustine/ADMINISTRATION & DOSAGE Procarbazine/ADMINISTRATION & DOSAGE ABSTRACT
970330
M9731531

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1997. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1997. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .